View printer-friendly version

<<  Back

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2017 Financial Results

LEXINGTON, Mass., Aug. 1, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced it will issue financial results for the second quarter ended June 30, 2017, on Tuesday, August 8, 2017, prior to the market open.

Aldeyra will hold a conference call on Tuesday, August 8, 2017, at 8:00 a.m. EDT to discuss the results.  The dial-in numbers are 1-877-870-4263 for domestic callers and 1-412-317-0790 for international callers.  A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.

About Aldeyra Therapeutics 
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.

Corporate Contact: 
Stephen Tulipano 
Aldeyra Therapeutics, Inc. 
Tel: +1 781-761-4904 ext. 205

Investor Contact: 
Chris Brinzey 
Westwicke Partners 
Tel: 339-970-2843

Media Contact: 
Cammy Duong  
MacDougall Biomedical Communications  


View original content:

SOURCE Aldeyra Therapeutics, Inc.

News Provided by Acquire Media